---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295834523.md"
description: "BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156."
datetime: "2026-08-13T18:29:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295834523.md)
  - [en](https://longbridge.com/en/news/295834523.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295834523.md)
generator: "portal-rs"
---

# 

BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.

### Related Stocks

- [BYSI.US](https://longbridge.com/en/quote/BYSI.US.md)

## Related News & Research

- [Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value](https://longbridge.com/en/news/288709929.md)
- [BeyondSpring posts investor deck highlighting plinabulin late-stage NSCLC program and immune-modulating approach](https://longbridge.com/en/news/296010507.md)
- [3 Promising Penny Stocks With Over $50M Market Cap](https://longbridge.com/en/news/296943644.md)
- [Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside](https://longbridge.com/en/news/296831532.md)
- [$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296847570.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**